# Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia

> **NCT07732907** · — · RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 15 (estimated)

## Conditions studied

- Multiple Sclerosis
- Progressive Multifocal Leukoencephalopathy

## Interventions

- **DRUG:** Ozanimod

## Key facts

- **NCT ID:** NCT07732907
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-04
- **Primary completion:** 2041-07-31
- **Final completion:** 2041-07-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07732907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07732907, "Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07732907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*